- Black & Edgington, where former Medeva managing director Ian Gowrie-Smith is executive chairman, is to enter the generic drug market with the signing of a license agreement for two sustained-release drugs for use in the treatment of diabetes. The products, glyburide (currently marketed as Glynase by Upjohn) and glipizide (sold as Glucotrol by Pfizer), are currently in development by Jago Pharma AG in Switzerland. Both products lose their patent protection within the next three years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze